FTC saying BrainStrong study not robust enough for claims

FTC saying BrainStrong study not robust enough for claims.

Recent FTC ruling discourages supplement research, Washington lawyer says

A proposed FTC consent decree finds that a study for BrainStrong was not sufficient to make congitive claims. Venable partner Todd Harrison says the high standard discourages research.

Todd Harrison says the cracks in DSHEA gaped a bit wider last month with the FTC’s proposed consent decree limiting claims by iHealth and Martek Biosciences for the BrainStrong Adult cognitive function supplement. The decree is a “shot through the heart” of the supplement industry, says Harrison, partner in Venable, a Washington D.C. law firm, and he worries whether the industry can mount the sort of response needed.

Register to view the full article

Register for NewHope.com and gain access to premium content including the Natural Products Industry Market Overview, webinars, and white papers.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.